QVM149 (Novartis) Drug Overview 2018 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--May 14, 2018--The “Drug Overview: QVM149” report has been added to ResearchAndMarkets.com’s offering.
QVM149 (Novartis) is a fixed triple combination product consisting of a long-acting muscarinic antagonist (glycopyrronium bromide), a long-acting beta 2 agonist (LABA) (indacaterol), and an inhaled corticosteroid (ICS) (mometasone furoate). QVM149 is in Phase III development for the treatment of moderate to severe asthma uncontrolled with standard ICS/LABA therapies.
Key Topics Covered:
List of Figures
Figure 1: Spiriva sales for asthma across the US, Japan, and five major EU markets, by country, 2017-26
Figure 2: Symbicort for asthma - SWOT analysis
List of Tables
Table 1: QVM149 drug profile
Table 2: QVM149 Phase III trials in asthma
Table 3: QVM149 sales for asthma across Japan and the five major EU markets, by country ($m), 2017-26
For more information about this report visit https://www.researchandmarkets.com/research/kj52wl/qvm149_novartis?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180514006238/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Asthma Drugs
INDUSTRY KEYWORD: HEALTH CLINICAL TRIALS PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 05/14/2018 02:52 PM/DISC: 05/14/2018 02:52 PM